NCT02379247 - BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

September 21, 2017

Study Completion Date

March 31, 2022

Conditions

Breast Cancer

Interventions

DRUG

BYL-719 (alpelisib)

Oral PI3K inhibitor

DRUG

Nab-paclitaxel

IV taxane

Trial Locations (4)

Vanderbilt-Ingram Cancer Center, Nashville

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

University of Kansas Cancer Center, Kansas City

University of Kansas Cancer Center - Overland Park, Overland Park